324 Results
Sort By:
Published on August 15, 2024
Investigators at the Children’s Hospital of Philadelphia (CHOP), St. Jude Children’s Research Hospital (St. Jude) and the Children’s Oncology Group (COG), have shown that non-coding DNA is responsible for as much 60% of the genetic changes that drive T-lineage acute lymphoblastic leukemia (T-ALL), an aggressive and high-risk form of the…
Published on July 26, 2024
French and Swiss researchers have uncovered the genetic and energetic characteristics of leukemic stem cells that are responsible for acute myeloid leukemia (AML) and suggest that blocking a specific iron utilization process of these cells provides an avenue for new therapeutic strategies to fight this disease. New approaches are desperately…
Published on June 26, 2024
Acute myeloid leukemia (AML) is a cancer of the bone marrow and the blood that progresses rapidly without treatment. Now, scientists at Purdue University’s College of Science and collaborators have developed a patent-pending compound called HSN748 to treat drug-resistant AML. Their findings are published in the Journal of Clinical Investigation in…
Published on April 9, 2024
A recent breakthrough by scientists at the St. Jude Children’s Research Hospital has shed light on which tumor cells in B-cell acute lymphoblastic leukemia (B-ALL) resist treatment and how this resistance can be overcome. The researchers, led by senior co-corresponding author Jun J. Yang, PhD, vice chair of the Department…
Published on February 2, 2024
Researchers from Sylvester Comprehensive Cancer Center, Memorial Sloan Kettering, and other institutions report that a new BTK-targeting drug compound has shown promise to overcome treatment resistance of chronic lymphocytic leukemia (CLL). The results of the Phase I research, published today in the journal Science, show that the compound called NX-2127…
Published on July 6, 2023
New findings may explain why some children with leukemia have a longer remission than others after having CAR T-cell therapy. Researchers at University College London (UCL), Great Ormond Street Hospital, and the Wellcome Sanger Institute identified a unique signature in chimeric antigen receptor (CAR) T-cells that are long lasting—a key…
Published on May 24, 2023
Researchers have been awarded new funding to develop therapies against a form of pediatric leukemia which generally has a poor prognosis. A team led by John H. Bushweller, PhD, of the University of Virginia School of Medicine, is leading the effort to create new therapeutic options for acute myeloid leukemia…
Published on April 26, 2023
Researchers led by a team from the Netherlands have shown that adding the immunotherapy blinatumomab to chemotherapy delays progression and improves survival for infants with an aggressive type of acute lymphoblastic leukemia (ALL). The study, published in the New England Journal of Medicine, found that the treatment, which has already been…
Published on April 11, 2023
Scientists at St. Jude Children’s Research Hospital have developed a novel combination therapy for a leukemia subtype harboring rearrangements in the KMT2A gene, which is more common in infants. The combination uses BET- and GSK3-inhibitors. The researchers report that based on laboratory work, their “synergistic” combinatorial approach overcomes the cancer’s drug resistance without adding…
Published on April 5, 2023
New findings from researchers at Linköping University in Sweden have shown that contrary to previous belief, stems cells remain in the bone marrow in acute lymphocytic leukemia. The disease, however, has been found to cause a hidden defect in the stem cells, that makes them lose their ability to form…
Published on March 16, 2023
Syndax’s revumenib showed promise in advanced acute leukemias with KMT2A rearrangements or mutant NPM1, according to findings from the Phase I AUGMENT-101 trial published this week in Nature. Formerly SNDX-5613, revumenib is an oral small-molecule inhibitor of the menin (MEN)-KMT2A interaction. Another study this week, also in Nature, explained the how MEN1 mutations play…
Published on February 22, 2023
A retrospective survival analysis conducted by researchers at Baylor College of Medicine and Texas Children’s Hospital found that children with acute lymphoblastic leukemia (ALL) who lived along the Texas border with Mexico were more likely to die within five years than those living in other areas of the state. The…
Published on January 5, 2023
A study by researchers at St. Jude Children’s Research Hospital delving into drug response across a swath of genetic subtypes of acute lymphoblastic leukemia (ALL), could provide a map for clinicians to more precisely match available treatments with a patient’s specific form of cancer. The results, from what the investigators…
Published on January 4, 2023
A type of chronic blood cancer called myeloproliferative neoplasms (MPN) can often be present in patients in a relatively benign state for years. Some patients require treatment, while others can undergo a period watchful waiting without treatment. However, in a small subset of these patients, this slower paced disease can…
Published on October 18, 2022
U.S. researchers at the University of California in Irvine have developed a mathematical model that they believe can help predict treatment response in patients with the white blood cell cancer chronic myeloid leukemia. The model identified patients most likely to respond well to treatment with tyrosine kinase inhibitors (TKIs) and…